[Therapy of chronic hepatitis C].
Interferon-alpha is still the only drug with antiviral activity against the hepatitis C virus. However, if the outcome of treatment is measured by highly sensitive virologic test, sustained response rates to interferon monotherapy are low, especially in patients infected with subtype 1 (3-10%). Therefore better therapies are needed. The combination of interferon with ribavirin is a major advance. Although the precise mode of action of ribavirin is unknown, it seems to decrease relapse rates after successful treatment. By combination therapy, 30% of patients with subtype 1 and 65% with subtype 3 had a sustained response. Further improvements can be expected from high-dose induction therapy and from long-acting pegylated interferons. Nonresponders may benefit from antifibrotic agents, like long-term interferon therapy, IL-10 or silymarin.